MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS.
MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS.
复制标题
多发性骨髓瘤。
DOI：
10.1001/jama.1964.03070100052010
复制
发表时间：
1964
期刊：
影响因子：
--
通讯作者：
H. Wilson
中科院分区：
文献类型：
--
作者：
D. Korst;G. Clifford;W. M. Fowler;J. Louis;J. Will;H. Wilson
21个机构对骨髓瘤治疗的合作研究已经进行了四年。1委员会遵循和评估了统一的方案、标准和数据流程表。2选择环磷酰胺(环磷酰胺)作为烷化剂，适用于低剂量、长程方案。这些结果是基于对165名接受药物治疗至少60天的患者的研究(这是一项“充分的试验”)。在开始这项研究的患者中，有20%(42人)因为死亡(17人)、并发症(8人)或失去随访(17人)而没有达到足够的试验状态。材料和方法参与研究的调查人员安排尽可能多的患者从各自的机构进行研究。多发性骨髓瘤的诊断是
A COOPERATIVE STUDY of a treatment of myeloma by 21 institutions has been in progress for four years.1A uniform protocol, criteria, and data flow sheets have been followed and evaluated by the committee. Comparison survival data with previous forms of treatment was obtained in an ancillary myeloma study by the same cooperative group in the same institutions.2Cyclophosphamide (Cytoxan) was selected as an alkylating agent suitable for use in a low oral dose, longrange program. These results are based on a study of 165 patients who received the drug for at least 60 days (an "adequate trial"). Twenty percent (42) of the patients who started the study did not reach adequate trial status because of death (17), complications (8), or loss to follow-up (17). Materials and Methods Participating investigators placed on study as many patients as possible from their respective institutions. The diagnosis of multiple myeloma was